Can-Fite Biopharma Ltd - ADR
CANF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.8M
Close$
$0.39
87.5% downside
Current Fair Value
87.5% downsideOvervalued by 87.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.80 Million |
|---|---|
| Enterprise Value | $-3,249,700.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.03 |
| Beta | 0.03 |
| Outstanding Shares | 11,381,886 |
Return
| Return on Equity | -157.33% |
|---|---|
| Return on Assets | -92.47% |
| Return on Invested Capital | -131.71% |
Valuation & Multiples
| P/E Ratio | -833.35 |
|---|---|
| PEG | -3588.22 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -5.8 |
| Enterprise Value to EBIT | 0.36 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.15 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 13, 2026
EPS Estimate
$-27.00
Average shareholder expectationRevenue Estimate
$300,000
Average shareholder expectationNext Earnings Call
Expected Date
August 27, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$218,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.24%▼ 4.10% |
|---|---|
| Total Invested | $271,361▼ 71.51% |
| Investors Holding | 14▼ 1.00% |
ESG Score
No data
About Can-Fite Biopharma Ltd
CEO: Pnina Fishman